These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 15799209

  • 21. The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: therapeutic implications.
    Chiarelli F, Verrotti A, Mohn A, Morgese G.
    Ann Med; 1997 Oct; 29(5):439-45. PubMed ID: 9453292
    [Abstract] [Full Text] [Related]

  • 22. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
    Lee GS.
    Ann Acad Med Singap; 2005 Jan; 34(1):24-30. PubMed ID: 15726216
    [Abstract] [Full Text] [Related]

  • 23. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.
    Harmankaya O, Seber S, Yilmaz M.
    Ren Fail; 2003 May; 25(3):465-70. PubMed ID: 12803510
    [Abstract] [Full Text] [Related]

  • 24. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T, Sato A, Hayashi K, Saruta T.
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [Abstract] [Full Text] [Related]

  • 25. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG.
    Cochrane Database Syst Rev; 2000 May; (2):CD002183. PubMed ID: 10796871
    [Abstract] [Full Text] [Related]

  • 26. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 27. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 28. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
    Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ.
    Diabet Med; 2011 Oct; 28(10):1182-7. PubMed ID: 21627686
    [Abstract] [Full Text] [Related]

  • 29. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC, Atkins RC.
    Drugs; 2006 Oct; 66(17):2213-34. PubMed ID: 17137404
    [Abstract] [Full Text] [Related]

  • 30. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
    Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD.
    Diabetes Obes Metab; 2016 Jun; 18(6):590-7. PubMed ID: 26936519
    [Abstract] [Full Text] [Related]

  • 31. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL, Toto RD, McCullough PA.
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [Abstract] [Full Text] [Related]

  • 32. Results from the TIP (Tritace in Proteinuria) intensified monitoring project.
    Mayer G, TIP Study Group.
    Kidney Blood Press Res; 2002 Feb; 25(2):80-6. PubMed ID: 12077488
    [Abstract] [Full Text] [Related]

  • 33. Does antihypertensive treatment prevent progression of microalbuminuria to overt proteinuria in insulin-dependent diabetic patients?
    Passa P.
    J Am Soc Nephrol; 1992 Oct; 3(4 Suppl):S91-6. PubMed ID: 1457766
    [Abstract] [Full Text] [Related]

  • 34. [Primary prevention of diabetic nephropathy].
    Trevisan R.
    G Ital Nefrol; 2012 Oct; 29 Suppl 58():S49-53. PubMed ID: 23229603
    [Abstract] [Full Text] [Related]

  • 35. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS.
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [Abstract] [Full Text] [Related]

  • 36. [Albuminuria in the diabetic patient: practical management].
    Kistler AD.
    Praxis (Bern 1994); 2013 Oct 02; 102(20):1229-35. PubMed ID: 24088233
    [Abstract] [Full Text] [Related]

  • 37. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.
    Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa GM, Nosadini R.
    Diabetes Care; 1998 Jan 02; 21(1):104-10. PubMed ID: 9538979
    [Abstract] [Full Text] [Related]

  • 38. Outcome studies in diabetic nephropathy.
    Mohanram A, Toto RD.
    Semin Nephrol; 2003 May 02; 23(3):255-71. PubMed ID: 12838494
    [Abstract] [Full Text] [Related]

  • 39. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.
    Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R.
    Ann Intern Med; 1998 Jun 15; 128(12 Pt 1):982-8. PubMed ID: 9625684
    [Abstract] [Full Text] [Related]

  • 40. How to protect the kidney in diabetic patients: with special reference to IDDM.
    Mogensen CE.
    Diabetes; 1997 Sep 15; 46 Suppl 2():S104-11. PubMed ID: 9285510
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.